Global private equity and venture capital news and research

Versant invests $25m in Series A for gene editing business CRISPR

24 Apr 2014

dnaVersant Ventures has invested $25m in Series A financing for biopharmaceutical business CRISPR Therapeutics, which is currently working on a breakthrough gene editing technology.

Tom Woiwode, venture partner at Versant, said, “We believe that CRISPR Therapeutics has immense potential, as it is uniquely positioned to translate this technology into human therapeutics, thanks to its foundational intellectual property and its multi-disciplinary team of experts, including senior industry executives, world-renowned academics, and clinicians.”

The company’s technology allows scientists and clinicians to mutate genes of interest and correct specific target genes, to tackle both recessive and dominant genetic diseases.

That genome editing offers significant advantages over traditional gene therapy approaches, which to date have only been useful in correcting some recessive genetic disorders, CRISPR said.

Last October healthcare-focused Versant officially launched its fifth fund with a $250m target, AltAssets revealed.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016